Multicell Technologies Inc (MCET) Financial Statements (2024 and earlier)
Company Profile
Business Address |
68 CUMBERLAND STREET, SUITE 301 WOONSOCKET, RI 02865 |
State of Incorp. | DE |
Fiscal Year End | November 30 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
5/31/2015 MRQ | 11/30/2014 | 11/30/2013 | 11/30/2012 | |||
---|---|---|---|---|---|---|
ASSETS | ||||||
Current Assets | ||||||
Cash, cash equivalents, and short-term investments | 113 | 146 | 199 | |||
Cash and cash equivalents | 113 | 146 | 199 | |||
Other current assets | 13 | 33 | ✕ | |||
Prepaid expense and other current assets | ✕ | ✕ | ✕ | 11 | ||
Total current assets: | 126 | 179 | 211 | |||
Noncurrent Assets | ||||||
Other noncurrent assets | 0 | 0 | ✕ | |||
Prepaid expense and other noncurrent assets | ✕ | ✕ | ✕ | 0 | ||
Total noncurrent assets: | 0 | 0 | 0 | |||
TOTAL ASSETS: | 126 | 179 | 211 | |||
LIABILITIES AND EQUITY | ||||||
Liabilities | ||||||
Current Liabilities | ||||||
Accounts payable and accrued liabilities, including: | 916 | 1,073 | 1,106 | |||
Other undisclosed accounts payable and accrued liabilities | 916 | 1,073 | 1,106 | |||
Debt | 45 | |||||
Deferred revenue and credits | 49 | 49 | 49 | |||
Due to related parties | 50 | 50 | 50 | |||
Other undisclosed current liabilities | 166 | 62 | 50 | |||
Total current liabilities: | 1,181 | 1,279 | 1,255 | |||
Noncurrent Liabilities | ||||||
Long-term debt and lease obligation | 36 | 56 | ||||
Long-term debt, excluding current maturities | 36 | 56 | ||||
Liabilities, other than long-term debt | 426 | 468 | 518 | |||
Deferred revenue and credits | 400 | 449 | 499 | |||
Derivative instruments and hedges, liabilities | 26 | 18 | 19 | |||
Total noncurrent liabilities: | 462 | 468 | 574 | |||
Total liabilities: | 1,643 | 1,747 | 1,830 | |||
Equity | ||||||
Equity, attributable to parent, including: | (144) | (363) | (539) | |||
Common stock | 45,528 | 26,108 | 13,498 | |||
Additional paid in capital | 16,557 | 27,756 | ||||
Accumulated deficit | (46,134) | (43,489) | (42,255) | |||
Other undisclosed equity, attributable to parent | 462 | 462 | 462 | |||
Equity, attributable to noncontrolling interest | (1,373) | (1,205) | (1,079) | |||
Total equity: | (1,517) | (1,567) | (1,618) | |||
TOTAL LIABILITIES AND EQUITY: | 126 | 179 | 211 |
Income Statement (P&L) ($ in thousands)
5/31/2015 TTM | 11/30/2014 | 11/30/2013 | 11/30/2012 | ||
---|---|---|---|---|---|
Revenues (Revenue, Net) | 49 | 49 | 49 | ||
Gross profit: | 49 | 49 | 49 | ||
Operating expenses | (772) | (1,417) | (1,624) | ||
Operating loss: | (723) | (1,368) | (1,575) | ||
Nonoperating income | 194 | 1 | 89 | ||
Investment income, nonoperating | (8) | 1 | 89 | ||
Interest and debt expense | 202 | (3) | 125 | ||
Loss from continuing operations: | (327) | (1,369) | (1,360) | ||
Loss before gain (loss) on sale of properties: | (327) | (1,369) | (1,360) | ||
Other undisclosed net income (loss) | (202) | 2 | |||
Net loss: | (529) | (1,369) | (1,359) | ||
Net income attributable to noncontrolling interest | 149 | 135 | 102 | ||
Net loss available to common stockholders, diluted: | (380) | (1,235) | (1,256) |
Comprehensive Income ($ in thousands)
5/31/2015 TTM | 11/30/2014 | 11/30/2013 | 11/30/2012 | ||
---|---|---|---|---|---|
Net loss: | (529) | (1,369) | (1,359) | ||
Comprehensive loss: | (529) | (1,369) | (1,359) | ||
Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 149 | (135) | (102) | ||
Comprehensive loss, net of tax, attributable to parent: | (380) | (1,504) | (1,461) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.